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A 59-year old female patient presented with apathy and 6 kg weight gain. Investigations revealed severe primary
hypothyroidism (TSH>100 μIU/ml). L-thyroxine (L-T4) was started and titrated up to 75 μg, once daily, with clinical
improvement. Other investigations revealed very high titres of anti-thyroid peroxidase (anti-TPO) and
anti-thyroglobulin (anti-Tg) antibodies. After three months, there was a fall in TSH to 12.74 μIU/ml, however, with
unexpectedly high free T4 (FT4) - 6.8 ng/ml and free T3 (FT3) - 6.7 pg/ml concentrations [reference range (rr): 0.8-1.9
ng/ml and 1.5-4.1 pg/ml (SiemensW), respectively]. At this stage L-T4 was stopped, and this was followed by a rapid
increase in TSH (to 77.76 μIU/ml) and some decrease in FT4 and FT3, however FT4 concentration remained elevated
(2.1 ng/ml). Following this, L-T4 was restarted. On admission to our Department, she was clinically euthyroid on
L-T4, 88 μg, once daily. Investigations on RocheW platform confirmed mildly elevated TSH - 5.14 (rr: 0.27-4.2 μIU/ml)
with high FT4 [4.59 (rr: 0.93-1.7 ng/ml)] and FT3 [4.98 (rr: 2.6-4.4 pg/ml)] concentrations. Other tests revealed
hypoechogenic ultrasound pattern typical for Hashimoto thyroiditis. There was no discrepancy in calculated TSH
value following TSH dilution (101% recovery). Concentrations of FT4 and FT3 were assessed on the day of
discontinuation of L-T4 and after four days by the means of Abbott
W Architect I 1000SR platform. These revealed
FT4 and FT3 concentrations within the reference range [e.g., FT4 - 1.08 ng/ml (rr: 0.7-1.48)] vs 4.59 ng/ml
(rr: 0.93-1.7, RocheW), FT3 - 3.70 pg/ml (rr: 1.71-3.71) vs 4.98 (rr: 2.6-4.4, Roche
W)], confirming assay interference.
Concentrations of ferritin and SHBG were normal.
Conclusions: Clinicians must be aware of possible assay interference, including the measurements of FT4 and FT3
in the differential diagnosis of abnormal results of thyroid function tests that do not fit the patient clinical
presentation.
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distribution, and reproduction in any medium(about 5–6 kg). Initial investigations revealed severe pri-
mary hypothyroidism (TSH>100 μIU/ml), moderate
hyperlipidaemia (total cholesterol 239 mg/dl, triglicer-
ides 185 mg/dl) and normal fasting glucose (83 mg/dl).
She was started on L-thyroxine (L-T4), 25 μg, once daily,
the dose of which was gradually titrated up to 75 μg,
once daily, with clinical improvement. Other investiga-
tions revealed very high titre of anti-thyroid peroxidase
antibodies (>4000 IU/ml (reference up to 115 IU/ml)).
After about 3 months of treatment test revealed
expected fall in TSH concentrations (to 12.74 μIU/ml),
however, with unexpectedly high free thyroxine (FT4)entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Initial results in the 59-year old female patient before and during treatment with L-T4
Date TSH FT4 FT3 L-T4 dose Reference Range
Initial results >100 - - none TSH 0.27-4.0 μIU/ml (SiemensW)
FT4 0.8-1.9 ng/ml (Siemens
W)
FT3 1.5-4.1 pg/ml (Siemens
W)
13-14 weeks 12.74 6.8 6.7 75 μg
16 weeks 77.76 2.1 4.0 None for two weeks
Seven months 49.23 3.1 4.5 50 μg
Twelve months 8.41 4.8 5.6 88 μg
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platform - see Table 1). At this stage L-T4 was stopped,
this was followed by a rapid increase in TSH (to 77.76
μIU/ml) and some decrease in FT4 and FT3, however,
FT4 concentration still remained elevated. Following
this, L-T4 was restarted. There was a gradual decrease in
TSH, with FT4 and FT3 concentrations above the refer-
ence range. The patient was referred for the second
opinion.
On admission to our Department, she was clinically eu-
thyroid. Her medication included L-T4, 88 μg, once daily,
Rosuvastatin, 10 mg, once daily, Amlodipine, 5 mg x 1,
once daily, Metoprolol slow release, 25 mg, once daily.
There was no overt history of angina. She did not smoke
and did not consume alcoholic beverages in excess.
Investigations performed in our Department (RocheW
platform) confirmed mildly elevated TSH with high FT4
and FT3 concentrations (Table 2). The patient vehe-
mently denied any compliance problems. Other tests
confirmed very high titres of anti-thyroid peroxidase
(anti-TPO) anti-thyroglobulin (anti-Tg) antibodies [anti-
Tg > 4000.00 IU/ml (rr: up to 115 IU/ml); anti-TPO
antibodies > 600.00 IU/ml (rr: up to 34 IU/ml)] and
hypoechogenic ultrasound pattern typical for Hashimoto
thyroiditis. Cortisol concentration was 10.52 μg/dl,
ACTH 14.7 pg/ml (rr: 0–46 pg/ml). There was no dis-
crepancy in calculated TSH value following TSH dilution
(Table 2). Following this, L-T4 was stopped with assess-
ment of thyroid function (Table 3). Again there was a
gradual increase of TSH with some decrease in FT4 and
FT3, however, still above the reference ranges. We also
assessed FT4 and FT3 on the day of discontinuation of
L-T4 and after 4 days in a different laboratory (Abbott
WTable 2 TSH dilution test in the 59-year old female
patient on 88 μg of L-T4 daily
Dilution TSH FT4 FT3 Reference Range
none 4.37 6.61 5.57 TSH 0.27-4.2 μIU/ml (RocheW)
FT4 0.93-1.7 ng/ml (Roche
W)
FT3 2.6-4.4 pg/ml (Roche
W)





- -Architect I 1000SR platform – Table 3). This revealed
FT4 and FT3 concentrations within reference ranges.
Furthermore, the measured FT4 concentration was
about 4 times lower than on the RocheW platform
(Table 3). Concentrations of ferritin and SHBG were
normal (Table 3). Following administration of a single
dose of 300 μg, once daily, there a was a decrease in
TSH with very little change of FT4 and FT3 (Roche
W
platform). Measurements of heterophilic antibodies were
unfortunately not available in our Department. A diag-
nosis of hypothyroidism due to Hashimoto thyroiditis
was made. The patient was discharged on L-T4, 100 μg,
once daily. The patient, as well as her GP were informed
about problems with FT4 and FT3 measurements, and
that further adjustments of L-T4 dose should be based
on clinical picture, as well as TSH measurements alone.
Discussion
Measurements of thyrotropin (TSH) and of total and
FT4 and FT3 are widely used for thyroid function evalu-
ation. However, some serum samples might demonstrate
a nonspecific binding with assay reagents that can inter-
fere with the measurement of these hormones. Several
authors have reported the presence of such interfer-
ences, resulting in abnormal concentrations of thyroid
hormones inconsistent with the patient's clinical picture
[1-3]. Interference in immunoassays is a widely recog-
nized problem, which could potentially lead to unneces-
sary investigations and treatment. We describe a case,
with interference in the FT4 and FT3 assay that led to
falsely elevated serum FT3 and FT4 concentrations.
Clinical and biochemical investigations of our patient
showed that biochemical thyroid status did not match
her clinical presentation. Namely, the patient had high
FT4 and FT3 levels with grossly elevated TSH, while
simultaneously she did not have clinical features of
hyperthyroidism. Further investigations revealed that she
had very high titres for anti-TPO antibodies and anti-Tg
antibodies, as well as thyroid ultrasound pattern typical
for Hashimoto thyroiditis. Moreover, following treat-
ment with L-T4, we observed an expected fall in TSH
concentrations, accompanied by clinical improvement,
but also accompanied by further increase of FT4 and
Table 3 Results of thyroid function tests in the 59-year old female patient during L-T4 withdrawal
Date TSH FT4 FT3 Ferritin SHBG Reference Ranges
14.06.2012# 5.14 4.59 4.98 79.9 TSH 0.27-4.2 μIU/ml (RocheW)
FT4 0.93-1.7 ng/ml (Roche
W)
FT3 2.6-4.4 pg/ml (Roche
W)
14.06.2012 not repeated: RocheW platform 1.08* 3.70* 79.5 *AbbottW Architect I 1000SR
FT4: 0.7-1.48 ng/dl
FT3: 1.71-3.71 pg/ml
15.06.2012 6.5 4.5 4.97 Ferritin: 5–148 ng/ml
16.06.2012 9.49 3.48 4.82 SHBG: 18.8-115.2 nmol/l
18.06.2012 11.01 3.41 4.74 81.00
18.06.2012## not repeated: RocheW platform 1.00* 3.38* 69.5 *AbbottW Architect I 1000SR
FT4: 0.7-1.48 ng/dl
FT3: 1.71-3.71 pg/ml
19.06.2012 9.53 3.57 4.74
# L-T4 stopped on this day.
## 300 μg of L-T4 administered after blood test on 18.06.2012.
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L-T4 withdrawal resulted in fast increase in TSH, with
only gradual decrease in FT4 and FT3, where FT4 still
remained above the reference range, despite very high
TSH concentration (see Table 1). For these reasons, we
considered assay interference. Therefore, we carried out
dilution in TSH serum, which demonstrated linear cor-
relation and almost 100% recovery. Manufacturer’s
instructions precluded dilution tests with FT4 and FT3
assays. Such situation was different from recently
described falsely elevated TSH level due to macro-TSH
[4]. Furthermore, investigations in our Department con-
firmed an expected rise of TSH after L-T4 withdrawal.
In our patient, based on biochemical studies alone, the
differential diagnosis also included thyroid hormone resist-
ance syndrome or a TSH-oma. Both entities are character-
ized by clinical thyrotoxicosis, diffuse goiters, elevated
circulating levels of FT4 and FT3, and non-suppressed
serum TSH, though such very high initial TSH concentra-
tions (i.e., above the upper limit of TSH assay), are not
typical for these entities. However, given significant clinical
improvement on L-T4 treatment, high antibody titres, as
well as thyroid ultrasound picture typical for Hashimoto
thyroiditis, we had decided not to perform either a TRH
test, or pituitary MR scanning. We are aware of the fact
that in case of thyroid hormone resistance or a TSH-oma
one might expect marked and progressive worsening of
thyrotoxicosis following gradual increase in the dose of L-
T4. Moreover, we also investigated concentrations of
SHBG and ferritin in serum. Thyroid hormone is one of
several factors that modulate the level of sex hormone-
binding globulin (SHBG) in serum. SHBG levels are usu-
ally elevated in thyrotoxicosis and have been reported to
be normal in a few patients with generalized resistance to
thyroid hormone (GRTH) [5,6]. Also, a significant body ofevidence exists showing a positive correlation between the
serum levels of T3, T4 and ferritin [7,8] in patients with ab-
normal thyroid status. Namely, all of these studies docu-
mented elevated serum ferritin levels in patients with
hyperthyroidism which normalized when the T3 and T4
levels returned to normal. In our patient levels of SHBG
and ferritin were normal.
For these reasons we concluded that assay interference
was the only plausible explanation for the observed ab-
normalities. As direct test for heterophilic antibodies
was not available in our institution, then we decided to
repeat the blood tests using a different assay (i.e. two
step assay – Abbott ArchitectW) in contrast to one step
SiemensW and RocheW assays. This showed markedly
lower concentration of FT4 and also lower concentration
of FT3, consistent with the clinical picture. A possibility
of assay interference is often under-recognised in clinical
practice, while some patients’ sera contain autoanti-
bodies to thyroid hormone that result in methodological
artifacts in total or free hormone measurements [9,10].
In such case, tracer T4 or T3 binds to the endogenous
heterophilic antibody and is subsequently falsely classi-
fied as bound to the sought substance by adsorption
methods, or alternatively - falsely classified as free by
double antibody methods, leading to falsely low or
falsely high serum total T4 or total T3 values, respect-
ively [10,11]. The T4 or T3 tracer analogs, used in some
FT4 or FT3 tests, may also bind to these autoantibodies,
leading to spuriously high serum FT4 and FT3 results.
Interference in thyroid hormones assays may thus cause
a mismatch between clinical and biochemical data and
lead to diagnostic dilemmas and inappropriate treat-
ment. Heterophilic antibodies are antibodies produced
against poorly defined antigens. They are generally weak
antibodies with multi-specific activities. Heterophilic
Lewandowski et al. Thyroid Research 2012, 5:11 Page 4 of 4
http://www.thyroidresearchjournal.com/content/5/1/11antibodies are present in 30-40% of the population.
However, they seldom cause interference with diagnostic
immunoassays (0.05-0.5%), unless present in particularly
high titres [12]. By definition, heterophilic antibodies are
directed against specific animal immunoglobulins or
against immunoglobulins of various animal species, de-
pending on the recognized epitope and on the cross-
reactivities between species immunoglobulins [10,13].
The recent development of two-site immunometric
assays with specific antibodies, such as mouse monoclo-
nal antibodies, has enabled higher specificities and sensi-
tivities. Since the introduction of these assays, there have
been several reports of abnormal concentrations of TSH
resulting from heterophilic antibody interference [10].
To counteract this problem, all commercial assays now
include blocking reagents, such as nonspecific and poly-
merized murine IgG. However, the presence of blocking
reagents does not completely eliminate the problem of
interference in some specimens and with some kits.
The FT4 and FT3 assays in our lab used a kit produced
by Roche Diagnosis GmbH, Mannheim (sandwich
Elecsys). Elecsys is an electrochemiluminescent immuno-
assay (ECLIA) involving ruthenium as the luminescent
material. To exclude interference, the thyroid function
tests were performed again, using the Architect system
(Abbott). The Architect FT3 and FT4 assay is a two-step
immunoassay determining the presence of free (unbound)
T3 and T4 in human serum and plasma using chemilu-
minescent microparticle immunoassay (CMIA). Unfortu-
nately, as we mentioned before, direct tests to detect
particularly high titres of heterophilic antibodies were not
available in our Department. However, given the patient's
clinical condition, results of other investigations, as well
as significant improvement in comfort after treatment
with L-T4, we concluded that the cause of disharmony be-
tween clinical picture and biochemical results was related
to FT4 and FT3 assay interference.
Conclusion
Clinicians need to be aware of the potential for interfer-
ence in immunoassays by heterophilic antibodies this
since such inaccurate results of thyroid function tests
may lead to inappropriate treatment decisions.
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